ArticleBMC infectious diseases2025
Tuberculosis incidence and treatment outcomes in the Tarmaber District, Ethiopia: a five-year retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence of Mycobacterium tuberculosis by using Gene Xpert and associated factors among presumptive for pulmonary tuberculosis patients attending at Debre Berhan Comprehensive Specialized Hospital, North Shoa Zone Amhara, Ethiopia 2025.BMC infectious diseases · 2026Article
- Tuberculosis surveillance indicators and chest radiograph phenotype clustering in southwestern Saudi Arabia, 2010-2020.Tropical medicine and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) remains a significant public health challenge in Ethiopia, despite ongoing efforts to enhance detection and treatment. Understanding the local TB incidence and treatment outcomes is essential for developing targeted control strategies. This study aimed to assess TB incidence and treatment outcomes over a five-year period in the Tarmaber district of the North Shewa Zone, Ethiopia.
methodsA five-year retrospective data were collected from TB registry books at Debre-Sina and Armanya Health Centers between January 1, 2014, and December 31, 2018. The study included 221 individuals diagnosed and treated under Directly Observed Treatment Short-course program. The study used passive case finding at the health centers, consistent with routine DOTS service delivery. Data on demographic characteristics, TB classification, HIV status, and treatment outcomes were extracted and analyzed using SPSS version 20. Descriptive statistics and chi-square tests were conducted to assess TB trends and associations with significance set at p < 0.05.
resultsAmong a total of 1,291 presumptive TB screened over five-years study period, 221 cases (17.1%) were confirmed as active tuberculosis. Of the 221 individuals suffering from TB, 79.2% had pulmonary TB (35.7% smear-positive and 43.4% smear-negative), and 19.9% had extra-pulmonary TB. It was more prevalent among males (52.5%) and individuals aged from 15 to 44 years (62%). Urban residents accounted for 56.6% of cases. The overall TB/HIV co-infection rate was 19%, with the majority (11.3%) being smear-negative. The average case detection rate for smear-positive TB was 35.8%, and the treatment success rate across the study period was 86.4%. A slight increase in TB incidence was observed in 2017.
conclusionThe study revealed a declining trend in TB incidence alongside relatively high treatment success rates. However, the low detection rate for smear-positive TB and the rising trend of TB/HIV co-infection highlights the need for strengthened diagnostic capacity, improved screening, and integrated TB/HIV services in the district.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.